Abstract: Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like;R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group;R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are selective agonists for 5-HT.sub.4 receptors. ##STR1## wherein Ak is a C.sub.3 -C.sub.6 alkyl group, and R is a C.sub.2 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 alkenyl group, a C.sub.3 -C.sub.6 alkynyl group, a C.sub.3 -C.sub.7 cycloalkyl group or a C.sub.3 -C.sub.6 cycloalkylmethyl group.

Abstract: An image processing system in which a process for implementing part of the display management function is provided separately from the window system or the operating system. In consequence, changes in the system configuration can be coped with only by conducting addition on a user program or the process which implements part of the display management function without modifying or altering the window system or the operating system. This eliminates modification or alteration of the window system or the operating program and increases the portability of the program.

Abstract: Diazabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, oxoalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, acyl, dialkylaminoalkyl, hydroxyalkyl, haloalkyl, cyanoalkyl, heterocycloalkyl, aryl, heteroarylalkyl or arylalkyl, the aryl group and the aryl moiety being optionally substituted by alkoxy, nitro, alkyl, amino or halo;R.sup.2 is hydrogen or alkyl;R.sup.3 and R.sup.4 may be the same or different and each is hydrogen, alkyl, alkenyl, acyl, alkoxyalkyl or arylalkyl wherein the aryl moiety is optionally substituted by alkoxy, nitro, alkyl, amino or halo;with the proviso that when R.sup.2 is hydrogen and both R.sup.3 and R.sup.4 are methyl, R.sup.1 does not represent hydrogen, alkyl, unsubstituted benzyl or dimethylaminoethyl; having 5-HT.sub.3 receptor antagonist activity.

Abstract: Azabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein A is a group of formula (a), (b) or (c): ##STR2## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.10 alkyl, aralkyl or di(C.sub.1 -C.sub.4) alkylamino(C.sub.1 -C.sub.6)alkyl;R.sub.2, R.sub.3 and R.sub.4 may be the same or different and each is hydrogen, amino, halogen, C.sub.1 -C.sub.4 alkoxy or phthalimide;X is O or NH;R is C.sub.1 -C.sub.4 alkyl; andY is NR, O or S;having 5-HT.sub.3 receptor antagonist activity.

Abstract: Disclosed are compounds of formula (I) ##STR1## in which A is ##STR2## The compounds are selective antagonists of 5HT at 5-HT.sub.3 receptors and useful in the treatment of psychotic disorders, neurotic diseases, gastric stasis symptoms, gastrointestinal disorders, nausea and vomiting.

Abstract: Azabicyclo derivatives of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein A is a group of formula (a), (b) or (c): ##STR2## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.10 alkyl, aralkyl or di(C.sub.1 -C.sub.4) alkylamino(C.sub.1 -C.sub.6)alkyl;R.sub.2, R.sub.3 and R.sub.4 may be the same or different and each is hydrogen, amino, halogen, C.sub.1 -C.sub.4 alkoxy or phthalimide; X is O or NH;R is C.sub.1 -C.sub.4 alkyl; andY is NR, O or S;having 5-HT.sub.3 receptor antagonist activity.

Abstract: Disclosed are compounds of formula I ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, benzyl or an indolyl carbonyl group, R.sub.2 is a saturated or unsaturated 5- or 8-membered heterocyclic group containing as a hetero atom one or more nitrogen atoms, the heterocyclic group is optionally substituted at an N or C atom by a C.sub.1 -C.sub.6 alkyl or aralkyl group, n is an integer of 1 to 5 and one or more hydrogen atoms, in an alkylene chain --(CH.sub.2).sub.n -- are optionally substituted by a C.sub.1 -C.sub.6 alkyl, phenyl and/or hydroxyl group, physiologically acceptable salts and quaternary ammonium salts thereof. The compounds are selective antagonists of 5-HT.sub.3 receptors and are useful in the treatment of psychotic disorders, neurotic diseases, gastric stasis symptoms, gastrointestinal disorders, nausea and vomiting.

Abstract: A tremolo device for a guitar includes an upper plate pivotably mounted about a first fulcrum on a guitar body, at least one spring urging the upper plate in one rotating direction, a part of the guitar body coming into contact with the upper plate to limit the rotation thereof in the one rotating direction, to bring the upper plate to a predetermined position, and a lower plate pivotably mounted about a second fulcrum and pulled in another direction opposite to the one direction by the tension of strings of the guitar. The rotation of the lower plate is limited by the upper plate in the predetermined position when the tremolo device is inactivated, and when the tremolo device is activated in such a manner that the lower plate is rotated in the other direction, the upper and lower plates are rotated together, but when the tremolo device is activated in such a manner that the lower plate is rotated inthe one direction, only the lower plate is rotated.

Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 is a nitro or trifluoromethyl group; R.sub.2 is a C.sub.1 -C.sub.6 alkyl group; R.sub.3 is a pyridyl or pyridyl N-oxide group which may be substituted with halogen, hydroxyl, haloalkyl, C.sub.1 -C.sub.6 alkoxy or C.sub.1 -C.sub.6 alkyl and further may be fused with a benzene or naphthalene ring, said ring being optionally substituted with C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halogen or haloalkyl, and a pharmaceutically acceptable acid addition salt thereof. The compounds of the formula (I) are of vasodilating and blood pressure lowering activities and thus may be useful for the treatment of cardiac diseases, cerebrovascular diseases and hypertension.

Abstract: Pipes of polypropylene reinforced with carbon fibers comprising 100 parts by weight of polypropylene, 10 to 40 parts by weight of a modified polypropylene by an organic unsaturated carboxylic acid or a copolymer of propylene and the organic unsaturated carboxylic acid and 5 to 70 parts by weight of carbon fibers of 5 to 30 micrometers in diameter and a ratio of diameter to length of 10 or more. The rate of retention of the original tensile strength of pipe in boiling water for 6 months at 100.degree. C. was higher than 95%.

Abstract: The present invention relates to a tower for drying gaseous chlorine, in which a high polymeric composite material containing carbon fibers and electroconductive carbon black as the whole or a part of the reinforcing material and the material for giving electroconductivity is used as a wall material thereof for removing static electricity generating within the tower.

Abstract: An electroconductive resin composite material for molding having excellent mechanical strength and electrical properties. The resin comprises 100 parts by weight of polypropylene, from 10 to 50 parts by weight of a modified polypropylene obtained either by chemically modifying polypropylene with an organic unsaturated carboxylic acid or by copolymerizing propylene and the organic unsaturated carboxylic acid, from 5 to 65 parts by weight of carbon fiber having a diameter of 5 to 20 micrometers, the ratio of length to diameter of the fiber being not less than 10, and from 5 to 65 parts by weight of electroconductive carbon black, the specific surface area being at least 800 m.sup.2 /g.

Abstract: The invention resides in an electrolytic cell element representing a frame structure defining partially an anode chamber and a cathode chamber. The frame is composed of a carbon fiber-high polymer composite material.